Reference number : 236-2017-2018-Q4-00567, amendment number : , agreement type : G, recipient legal name : Gleave, Martin E, recipient country : CA, recipient province : BC, recipient city : Vancouver, recipient postal code : V6T 1Z1, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 351900.0, agreement start date : 2018-04-01, agreement end date : 2020-03-31, description english : Preclinical development of a novel androgen receptor antagonist to treat castration-resistant prostate cancer, description french : Preclinical development of a novel androgen receptor antagonist to treat castration-resistant prostate cancer, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2018-19 to 2019-20), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2018-19 à 2019-20), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada